DoD Melanoma Research program funding opportunities for FY2019

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

April 17, 2026

By Paul Goldberg

Guest Editorial

Most Favored Nation drug pricing could put China on top

China’s biotech sector is rapidly becoming a global innovation powerhouse. In oncology alone, Chinese licensing deals reached $30 billion in 2024—triple the United States’ output. Nearly a third of the world’s clinical trials now take place in China.

April 17, 2026

By John Stanford

Bridging communication and genomics: A path toward equitable cancer care

The era of genomic oncology is defined by complexity. Over the last decades, we have moved from single-gene tests to multi-gene panels and, eventually, will be routinely using whole-exome/whole-genome and transcriptome sequencing in clinical care.

April 17, 2026

By Stacy W. Gray

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

A meeting convened by Friends of Cancer Research focused on the methodology for using external control arms in cancer clinical trials.

April 17, 2026

By Jacquelyn Cobb

DoD Melanoma Research program funding opportunities for FY2019

YOU MAY BE INTERESTED IN

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

Most Favored Nation drug pricing could put China on top

Bridging communication and genomics: A path toward equitable cancer care

FDA adds stereotactic breast biopsy needles to the shortage list

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

Renew today!

Subscriber content

Never miss an issue!

Login

DoD Melanoma Research program funding opportunities for FY2019

YOU MAY BE INTERESTED IN

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0

Most Favored Nation drug pricing could put China on top

Bridging communication and genomics: A path toward equitable cancer care

FDA adds stereotactic breast biopsy needles to the shortage list

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

Never miss an issue!

Login

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0